Literature DB >> 7670956

Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma.

Y Huang1, A von Eckardstein, S Wu, G Assmann.   

Abstract

HDLs encompass structurally heterogeneous particles that fulfill specific functions in reverse cholesterol transport. Two-dimensional nondenaturing polyacrylamide gradient gel electrophoresis (2D-PAGGE) of normal plasma and subsequent immunoblotting with anti-apolipoprotein (apo) A-I antibodies differentiates an abundant particle with electrophoretic alpha-mobility and less abundant particles with electrophoretic pre-beta-mobility (pre beta 1-LpA-I, pre beta 2-LpA-I, pre beta 3-LpA-I). Immunodetection with anti-apoA-II antibodies identifies a single particle with alpha-mobility. To differentiate alpha-migrating HDL without apo A-II (alpha-LpA-I) from those with apoA-II (alpha-LpA-I/A-II), we combined 2D-PAGGE with immunoadsorption of apoA-II. Incubation of plasma with [3H]cholesterol-labeled fibroblasts in combination with immunosubtracting 2D-PAGGE allowed us to analyze the role of alpha-LpA-I and alpha-LpA-I/A-II in the uptake and esterification of cell-derived cholesterol in native plasma. Depending on the duration of incubations with cells, alpha-LpA-I took up two to four times more [3H]cholesterol than alpha-LpA-I/A-II. Irrespective of the duration of incubation, two to three times more [3H]cholesteryl esters accumulated in alpha-LpA-I than in alpha-LpA-I/A-II. Subsequent incubations in the presence of an inhibitor of lecithin:cholesterol acyltransferase led to preferential accumulation of [3H]cholesteryl esters in alpha-LpA-I/A-II. In conclusion, our data indicate that alpha-LpA-I is more effective than alpha-LpA-I/A-II in both uptake and esterification of cell-derived cholesterol. Moreover, alpha-LpA-I/A-II appears to accumulate cholesteryl esters, at least partially, from alpha-LpA-I.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670956     DOI: 10.1161/01.atv.15.9.1412

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Speciated human high-density lipoprotein protein proximity profiles.

Authors:  Kekulawalage Gauthamadasa; Corina Rosales; Henry J Pownall; Stephen Macha; W Gray Jerome; Rong Huang; R A Gangani D Silva
Journal:  Biochemistry       Date:  2010-11-23       Impact factor: 3.162

Review 2.  ACP Broad Sheet no 151: September 1997. Investigation of dyslipidaemias.

Authors:  A F Winder; W Richmond; D T Vallance
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

3.  Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility.

Authors:  W Weng; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein (HDL): protein conformational ensemble on HDL.

Authors:  Xuan Gao; Shujun Yuan; Shobini Jayaraman; Olga Gursky
Journal:  Biochemistry       Date:  2012-06-01       Impact factor: 3.162

5.  Apolipoprotein A-II: still second fiddle in high-density lipoprotein metabolism?

Authors:  Alan T Remaley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

6.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

7.  Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins.

Authors:  Corina Rosales; Baiba K Gillard; Harry S Courtney; Francisco Blanco-Vaca; Henry J Pownall
Journal:  Biochemistry       Date:  2009-08-25       Impact factor: 3.162

8.  Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.

Authors:  Esther M M Ooi; Gerald F Watts; Paul J Nestel; Dmitri Sviridov; Anh Hoang; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

9.  Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease.

Authors:  James Ronald; Ramakrishnan Rajagopalan; Jane E Ranchalis; Julieann K Marshall; Thomas S Hatsukami; Patrick J Heagerty; Gail P Jarvik
Journal:  Lipids Health Dis       Date:  2009-12-01       Impact factor: 3.876

10.  Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Kerry-Anne Rye; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Diabetes Care       Date:  2009-08-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.